Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia.
- Author:
Yi-Yun YAO
1
;
Qi ZHU
;
Li-Fang ZOU
;
Hong-Ju DOU
;
Yi-Min CHEN
;
Yong TANG
;
Jun-Pei HU
Author Information
1. Department of Hematology, Shanghai Ninth People Hospital, Shanghai Jiaotong University Medical College, Shanghai, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cytarabine;
administration & dosage;
Female;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
Male;
Middle Aged;
Recurrence;
Vidarabine;
administration & dosage;
analogs & derivatives
- From:
Journal of Experimental Hematology
2009;17(3):774-776
- CountryChina
- Language:Chinese
-
Abstract:
The aim of study was to evaluate the clinical efficacy and toxicity of fludarabine combined with cytarabine (FA) regimen in the treatment of patients with refractory and/or relapsed acute myeloid leukemia (AML). Nineteen cases with refractory/relapsed AML were treated with FA regimen in which fludarabine phosphate 25 mg/(m(2) x d), d1-5; cytarabine (Ara-C) 2 g/(m(2) x d), d1-5. Another 20 cases were treated with salvage chemotherapy (MAE regimen: mitoxantrone, Ara-C and etoposide or DAE regimen: daunorubicin, Ara-C and etoposide). All patients received at least 2 cycles chemotherapy. The results showed that 9 patients (47%) in FA regimen group achieved complete remission (CR), 8 cases (42%) obtained partial remission (PR), the clinical efficacy was superior to that of the MAE or DAE regimens (p < 0.05). Major toxicity of FA regimen was myelosuppression. Grade IV hematologic toxicity occurred in all patients received FA regimen. Nonhematologic complications consisted of gastrointestinal side effects, mucositis, liver toxicity, which were mild to moderate and could be alleviated with supportive therapy. In conclusion, FA regimen is an effective regimen for treatment of refractory and relapsed AML.
